Advanced search
Publication Cover
Acta Cardiologica Volume 74, 2019 - Issue 1
Submit an article Journal homepage
53
Views
0
CrossRef citations to date
0
Altmetric
Original Scientific Paper

The predictive role of modified TIMI risk index in patients with ST-segment elevation myocardial infarction

Adnan KayaDepartment of Cardiology, Duzce University, Duzce, Turkey;
,
Muhammed KeskinDepartment of Cardiology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey; Correspondence[email protected]
,
Tolga Sinan GüvençDepartment of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey;
,
Mustafa Adem TatlısuDepartment of Cardiovascular Science, Texas A&M Institute for Preclinical Studies, Texas A&M University, College Station, TX, USA
&
Osman KayapınarDepartment of Cardiology, Duzce University, Duzce, Turkey;
Pages 29-36 | Received 27 Jun 2017, Accepted 07 Feb 2018, Published online: 23 Feb 2018

References

  • Ochiai M, Isshiki T, Takeshita S, et al. Relation of duration of ST reelevation at reperfusion and improvement of left ventricular function after successful primary angioplasty of the left anterior descending coronary artery in anterior wall acute myocardial infarction. Am J Cardiol. 1997;79:1667–1670.
  • Acet H, Ertas F, Akil MA, et al. The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. Turk J Med Sci. 2016;46:604–613.
  • Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–842.
  • Califf RM, Woodlief LH, Harrell FE Jr, et al. Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. Am Heart J. 1997;133:630–639.
  • Hillis LD, Forman S, Braunwald E. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. J Am Coll Cardiol. 1990;16:313–315.
  • Kurt IH, Batur MK, Unal I. The effect of streptokinase therapy in STEMI and conventional therapy in NSTEMI patients on TIMI risk index, B-type natriuretic peptide and high-sensitive C-reactive protein. Anadolu Kardiyol Derg. 2011;11:530–535.
  • Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031–2037.
  • Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44:783–789.
  • Aronson D, Hammerman H, Beyar R, et al. Serum blood urea nitrogen and long-term mortality in acute ST-elevation myocardial infarction. Int J Cardiol. 2008;127:380–385.
  • Ekmekçi A, Keskin M, Güvenç TS, et al. Usefulness of the thrombolysis in myocardial infarction risk index in acute heart failure: a pilot study. Am J Emerg Med. 2016; 34:2351–2355.
  • Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501–2555.
  • Bradshaw PJ, Ko DT, Newman AM, et al. Validation of the thrombolysis in myocardial infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. Can J Cardiol. 2007;23:51–56.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.